AdaptiSPECT-C: A Next-Generation, Adaptive Brain-Imaging SPECT System for Drug Discovery and Clinical Imaging

AdaptiSPECT-C：用于药物发现和临床成像的下一代自适应脑成像 SPECT 系统

• 批准号: 9335344
• 负责人: LARS R FURENLID
• 金额: $ 103.12万
• 依托单位: UNIV OF MASSACHUSETTS MED SCH WORCESTER
• 依托单位国家: 美国
• 财政年份: 2016
• 资助国家: 美国
• 起止时间: 2016-09-01 至 2021-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9335344
• 关键词: Anatomy; Arizona; Biological Markers; Biomedical Research; Brain; Brain Diseases; Brain imaging; Calibration; Characteristics; Clinic; Clinical; Clinical Data; Code; Collimator; Computer software; Contracts; Data; Dementia; Detection; Development; Diagnostic; Differential Diagnosis; Dimensions; Discipline of Nuclear Medicine; Disease; Distributional Activity; Documentation; Dose; Drug Industry; Drug Kinetics; FDA approved; Face; Gamma Rays; Generations; Geometry; Head; Human; Image; Image Analysis; Imaging Device; Inflammation; Institution; Kinetics; Label; Lead; Lesion; Magnetic Resonance Imaging; Maps; Massachusetts; Mechanics; Modeling; Monitor; Motion; Names; Patient Care; Patients; Performance; Pharmacologic Substance; Phase; Photons; Positron-Emission Tomography; Protocols documentation; Radiation; Radioisotopes; Radionuclide Imaging; Radiopharmaceuticals; Research Contracts; Resolution; Rotation; Safety; Sampling; Self-Correction; Sensory Receptors; Slice; Specificity; Structure; Surface; System; Systems Analysis; Testing; Therapy Evaluation; Tracer; Universities; Variant; attenuation; base; biomarker development; clinical application; clinical imaging; commercialization; cost; design; detector; diagnosis evaluation; drug discovery; flexibility; human imaging; human subject; imaging agent; imaging system; improved; individual patient; innovation; molecular imaging; next generation; novel therapeutics; performance tests; pre-clinical; prototype; quantitative imaging; reconstruction; response; single photon emission computed tomography; tool

Advances in molecular imaging are yielding a new generation of single-photon-emission-computed- tomography (SPECT) brain-imaging agents that will lead the way in understanding the human brain by enabling the development of biomarkers with unprecedented specificity for mapping neuroreceptors and proteinopathies associated with disease and dementia. SPECT is an ideal tracer-imaging tool for investigating the underlying mechanisms in brain disorders, their differential diagnoses, and monitoring their treatment because of its lower cost and radiation dose relative to PET, longer half-lives of the radionuclides imaged, and ability to simultaneously image multiple imaging agents labeled with different radionuclides. However, most clinical brain SPECT is still being performed by 2-headed systems with collimators designed for planar scintigraphy. To meet the potential for better patient care offered by these new imaging agents, and vastly improve the utility of existing agents, a revolution in SPECT brain-imaging system design is required. In Phase 1 of this Biomedical Research Partnership (BRP) application we propose to meet this requirement by creating a multi-detector-module multi-pinhole (MPH) SPECT brain-imaging system ideally suited for quantitative dynamic and high-spatial-resolution static SPECT imaging. Based on its heritage and intent for clinical imaging, we have named this proposed system AdaptiSPECT-C. Dynamic imaging will be enabled by obtaining sufficient angular sampling without the need for rotation. The system will automatically adapt its imaging characteristics (aperture size and number of pinholes open for imaging) in response to the imaging tasks and individual patients. It will thereby optimize lesion detection and quantification, as well as provide optimal data for pharmacokinetic analysis within structures throughout the brain. Automatic alignment to existent CT diagnostic studies of the patient for use in providing anatomical correlation, formation of attenuation maps, and templates for PVE correction will be enabled through usage of depth- sensing cameras, which will also be used for correction for head motion. Comparison of AdaptiSPECT-C to clinical systems will be conducted through inviCRO, one of the nation's top contract research organizations (CROs) serving the pharmaceutical industry. These studies will provide the documentation of system performance necessary to enable “Big-Pharma” companies to use the system to gather the clinical data necessary for FDA approval of new pharmaceuticals. Our Specific Aims are: 1. Construct an adaptable brain-SPECT system and test performance versus design specifications; 2. Develop reconstruction software for optimal image quality and activity quantification; 3.Integrate depth-sensing camera imaging to correct patient motion and align existent CT slices; and 4. Incorporate analysis software, and validate system through prototype human imaging.

分子成像的进步正在产生新一代的单光子发射计算 断层扫描（SPECT）大脑成像剂，将导致理解人脑的道路 实现具有前所未有的特异性生物标志物来映射神经受体和 与疾病和痴呆有关的蛋白质病。 SPECT是理想的示踪图像工具 研究脑疾病中的潜在机制，其鉴别诊断和监测 由于其成本较低和辐射剂量相对于PET的治疗，Radiouclides的半衰期更长 成像，并能够简单地成像用不同放射线标记的多个成像剂。 但是，大多数临床大脑SPECT仍在设计的2头系统中进行，这些系统设计了 用于平面闪烁显像。为了满足这些新成像剂提供更好患者护理的潜力， 并大大改善了现有代理的效用，Spect脑成像系统设计的革命是 必需的。 在本生物医学研究伙伴关系（BRP）应用程序的第一阶段中，我们建议符合此项 通过创建多探测器模块多针孔（MPH）SPECT脑成像系统的需求 适合定量动态和高空间分辨率静态SPECT成像。根据其遗产和 临床成像的意图，我们命名了此拟议的系统Adaptispect-C。动态成像将是 通过获得足够的角度采样而无需旋转来启用。系统将自动 根据响应 成像任务和个别患者。因此，它将优化病变检测和量化，以及 在整个大脑的结构内提供最佳数据，以进行药代动力学分析。自动的 与患者的现有CT诊断研究保持一致，以提供解剖相关性， 衰减图的形成和PVE校正模板将通过深度使用 - 传感摄像机，也将用于校正头部运动。 Adaptispect-C与 临床系统将通过美国顶级合同研究组织之一Invicro进行 （CRO）为制药行业服务。这些研究将提供系统的文档 使“ Big-Pharma”公司能够使用该系统收集临床数据所需的性能 FDA批准新药所必需的。 我们的具体目的是：1。构建适应性的脑光谱系统和测试性能与 设计规格； 2。开发重建软件以进行最佳图像质量和活动 定量； 3.整合深度感应摄像头成像以纠正患者运动并对齐现有CT 切片；和4。合并分析软件，并通过原型人体成像验证系统。